Comparative characteristics of patients with cytogenetic aberrations in MSCs, patients with a normal MSC karyotype, and a control group of healthy donors
| . | MSCs with aberrations (n = 15) . | MSCs with normal karyotype (n = 79) . | Healthy donors (n = 36) . |
|---|---|---|---|
| Median age, y (range) | 59 (26-83) | 62 (19-84) | 48 (21-86) |
| Sex, male/female ratio | 10/5 | 59/20 | 17/19 |
| MSC culture time, median (range) | 30 (23-49) | 34 (18-76) | 33 (22-57) |
| Number of MSC passages, median (range) | 4 (3-5) | 4 (3-8) | 4 (3-8) |
| s-AML, n (%) | 5 (50%)* | 14 (34%)* | |
| Cytogenetic aberrations in HCs, n (%) | 8 (53%)* | 33 (42%)* | |
| Unfavorable prognostic genetic and cytogenetic aberrations in HCs, n (%) | 8 (53%)† | 15 (19%)† | |
| Overall mortality, n (%) | 9 (60%)† | 23 (29%)† | |
| Leukemia-related mortality, n (%) | 4 (44%)† | 6 (26%)† |
| . | MSCs with aberrations (n = 15) . | MSCs with normal karyotype (n = 79) . | Healthy donors (n = 36) . |
|---|---|---|---|
| Median age, y (range) | 59 (26-83) | 62 (19-84) | 48 (21-86) |
| Sex, male/female ratio | 10/5 | 59/20 | 17/19 |
| MSC culture time, median (range) | 30 (23-49) | 34 (18-76) | 33 (22-57) |
| Number of MSC passages, median (range) | 4 (3-5) | 4 (3-8) | 4 (3-8) |
| s-AML, n (%) | 5 (50%)* | 14 (34%)* | |
| Cytogenetic aberrations in HCs, n (%) | 8 (53%)* | 33 (42%)* | |
| Unfavorable prognostic genetic and cytogenetic aberrations in HCs, n (%) | 8 (53%)† | 15 (19%)† | |
| Overall mortality, n (%) | 9 (60%)† | 23 (29%)† | |
| Leukemia-related mortality, n (%) | 4 (44%)† | 6 (26%)† |
Statistical analysis was performed using Student t test and unpaired 2-sided exact Fisher test. Unfavorable prognostic genetic and cytogenetic aberrations are complex aberrations (3 or more aberrations pro metaphase), monosomy 5 or 7, del(5q) in AML patients, t(11;19)(q11;p13.1), and FLT3 mutation.2 Other abbreviations are explained in Table 1.
Not significant.
P < .05.